Company Description
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity.
The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients.
Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021.
The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
| Country | United States |
| Founded | 2010 |
| IPO Date | Feb 2, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 102 |
| CEO | Harith Rajagopalan |
Contact Details
Address: 3 Van de Graaff Drive, Suite 200 Burlington, Massachusetts 01803 United States | |
| Phone | 781 902 8800 |
| Website | fractyl.com |
Stock Details
| Ticker Symbol | GUTS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001572616 |
| ISIN Number | US35168W1036 |
| Employer ID | 27-3553477 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Harith Rajagopalan | Chief Executive Officer |
| Lisa Davidson | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 4, 2024 | 8-K | Current Report |
| Sep 12, 2024 | 144 | Filing |
| Aug 14, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 10-Q | Quarterly Report |
| Jul 30, 2024 | 8-K | Current Report |
| Jun 24, 2024 | 8-K | Current Report |